Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells
| dc.contributor.author | Patel, H | |
| dc.contributor.author | Mothia, B | |
| dc.contributor.author | Patel, J | |
| dc.contributor.author | Fasanya, O | |
| dc.contributor.author | Sooda, K | |
| dc.contributor.author | Javid, F | |
| dc.contributor.author | Wyatt, PB | |
| dc.date.accessioned | 2020-05-15T10:04:09Z | |
| dc.date.available | 2020-05-15T10:04:09Z | |
| dc.date.issued | 2020-06 | |
| dc.identifier.citation | Patel, Hinal et al. "Cytotoxicity Of Some Synthetic Bis(Arylidene) Derivatives Of Cyclic Ketones Towards Cisplatin-Resistant Human Ovarian Carcinoma Cells". Medicinal Chemistry Research, vol 29, no. 6, 2020, pp. 935-941. Springer Science And Business Media LLC, doi:10.1007/s00044-020-02532-5. Accessed 15 May 2020. | en_US |
| dc.identifier.issn | 1054-2523 | |
| dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/64105 | |
| dc.description.abstract | Symmetrical α,αʹ-bis(arylidene)ketones were prepared by acid-catalyzed aldol condensations between aliphatic ketones (e.g., cyclopentanone, 4-alkylcyclohexanones, tetrahydropyran-4-one, and tetrahydrothiopyran-4-one) and two equivalents of an aromatic hydroxyaldehyde (e.g., 4-hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, vanillin, isovanillin, and 3-fluoro-4-hydroxybenzaldehyde). Most of the compounds were cytotoxic towards the cisplatin-resistant human ovarian cancer cell line A2780-CP70 as well as the non-resistant line A2780. | en_US |
| dc.language | en | |
| dc.publisher | Springer Science and Business Media LLC | en_US |
| dc.relation.ispartof | Medicinal Chemistry Research | |
| dc.rights | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. | |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title | Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells | en_US |
| dc.type | Article | en_US |
| dc.rights.holder | © The Author(s) 2020 | |
| dc.identifier.doi | 10.1007/s00044-020-02532-5 | |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Published online | en_US |
| rioxxterms.funder | Default funder | en_US |
| rioxxterms.identifier.project | Default project | en_US |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
